Total lymphoid irradiation ( DrugBank: - )

3 diseases

ID	Disease name (Link within this page)	Number of trials
65	Primary immunodeficiency	1
284	Diamond-Blackfan anemia	1
326	Osteopetrosis	2

65. Primary immunodeficiency

Clinical trials : 482 / Drugs : 653 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00176878 (ClinicalTrials.gov)	June 2000	12/9/2005	Stem Cell Transplant for Bone Marrow Failure Syndromes	Bone Marrow Transplantation for Non-Malignant Congenital Bone Marrow Failure Disorders	Diamond-Blackfan Anemia;Kostmann's Neutropenia;Shwachman-Diamond Syndrome	Procedure: Stem cell transplant;Drug: Fludarabine monophosphate;Procedure: Total lymphoid irradiation;Drug: Busulfan;Biological: anti-thymocyte globulin	Masonic Cancer Center, University of Minnesota	NULL	Completed	N/A	35 Years	All	10	Phase 2/Phase 3	United States

Clinical trials : 37 / Drugs : 110 - (DrugBank : 34) / Drug target genes : 23 - Drug target pathways : 124

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00176878 (ClinicalTrials.gov)	June 2000	12/9/2005	Stem Cell Transplant for Bone Marrow Failure Syndromes	Bone Marrow Transplantation for Non-Malignant Congenital Bone Marrow Failure Disorders	Diamond-Blackfan Anemia;Kostmann's Neutropenia;Shwachman-Diamond Syndrome	Procedure: Stem cell transplant;Drug: Fludarabine monophosphate;Procedure: Total lymphoid irradiation;Drug: Busulfan;Biological: anti-thymocyte globulin	Masonic Cancer Center, University of Minnesota	NULL	Completed	N/A	35 Years	All	10	Phase 2/Phase 3	United States

Clinical trials : 20 / Drugs : 51 - (DrugBank : 14) / Drug target genes : 17 - Drug target pathways : 81

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00775931 (ClinicalTrials.gov)	August 2008	16/10/2008	Allogeneic Transplantation For Severe Osteopetrosis	Allogeneic Hematopoietic Stem Cell Transplantation For Severe Osteopetrosis	Severe Osteopetrosis	Procedure: umbilical cord blood transplantation;Drug: Campath-1H;Radiation: Total Lymphoid Irradiation;Drug: Cyclophosphamide;Drug: Busulfan;Drug: Fludarabine monophosphate;Procedure: marrow graft transplantation	Masonic Cancer Center, University of Minnesota	NULL	Completed	N/A	45 Years	All	7	Phase 2/Phase 3	United States
2	NCT00638820 (ClinicalTrials.gov)	September 2007	11/3/2008	Reduced Intensity AlloTransplant For Osteopetrosis	Reduced Intensity Allogeneic Transplantation For Severe Osteopetrosis Incorporating A Second Cd34 Selected Graft	Osteopetrosis	Procedure: Stem Cell or Umbilical Cord Blood Transplantation;Drug: Campath, Busulfan, Clofarabine;Procedure: Total Lymphoid Irradiation	Masonic Cancer Center, University of Minnesota	NULL	Terminated	N/A	45 Years	All	3	Phase 2	United States